List of Evrysdi drug patents
Evrysdi is owned by Genentech Inc.
Evrysdi contains Risdiplam.
Evrysdi has a total of 3 drug patents out of which 0 drug patents have expired.
Evrysdi was authorised for market use on 07 August, 2020.
Evrysdi is available in for solution;oral dosage forms.
Evrysdi can be used as treatment of spinal muscular atrophy.
Drug patent challenges can be filed against Evrysdi from 2024-08-07.
The generics of Evrysdi are possible to be released after 04 October, 2038.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9586955 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
Feb, 2033
(9 years from now) | |
| US9969754 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
May, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11534444 | GENENTECH INC | Treatment of SMA |
Oct, 2038
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | May 27, 2029 |
| New Chemical Entity Exclusivity (NCE) | Aug 7, 2025 |
| New Patient Population (NPP) | May 27, 2025 |
Drugs and Companies using RISDIPLAM ingredient
NCE-1 date: 2024-08-07
Market Authorisation Date: 07 August, 2020
Treatment: Treatment of spinal muscular atrophy
Dosage: FOR SOLUTION;ORAL
EVRYSDI family patents
12
United States
5
European Union
4
Israel
4
Korea, Republic of
4
EA
3
Australia
3
Hungary
3
Morocco
3
Philippines
3
Singapore
3
Taiwan, Province of China
3
China
3
Japan
2
Denmark
2
Mexico
2
Costa Rica
2
Argentina
2
Brazil
2
Spain
2
Peru
2
Poland
2
Chile
2
Ukraine
2
Canada
2
New Zealand
1
South Africa
1
Turkey
1
Hong Kong
1
Slovenia
1
Lithuania
1
Norway
1
Croatia
1
Colombia
1
Portugal
1
Netherlands
1
RS
1
Ecuador
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic